Gonadorelin, or gonadotropin-releasing hormone, is sometimes known by its acronym, GnRH. Research shows that luteinizing and follicle-stimulating hormones are secreted with this synthetic decapeptide, and its primary function is related to infertility in 2023.

Today, GnRH is used for testing on animal test subjects with infertility [i], hypogonadism, or menstrual cycle problems. Gonadorelin peptide has shown promise in the treatment of breast and prostate cancer, as well as in the management of Alzheimer’s disease, according to the findings of recent studies.

Gonadorelin: what is it?

Studies reveal that the hormones follicle-stimulating hormone (FSH) and luteinizing hormone (LH) are secreted from the anterior pituitary by Gonadorelin (LH). Researchers have shown that these hormones promote follicular development and ovulation.

Although Gonadorelin (Gn) isn’t a novel therapeutic peptide, scientists are interested in GnRH analogs and their effects on mouse physiology.

Scientists have developed a cure for prostate cancer since they understand that Gonadorelin may have a role in curing the disease. It displays a success rate of 99 percent when tested on animals with prostate cancer.

More research on Gonadorelin might lead to breakthroughs in treating diseases, including breast cancer and Alzheimer’s, the researchers say.

Gonadorelin’s Advantages

Infertility

Research suggests that the production of FSH and LH from the pituitary gland in response to GnRH causes the ovaries in females to develop and ovulate. The testes in males generate sperm. According to studies, hormones like testosterone in males and estrogen and progesterone in females are produced by the ovaries and testes, respectively, after being stimulated by these two hormones [ii].

Studies revealed that waves of GnRH peptide are intermittently released. Pulses occur regularly in male mice but are cycle-dependent in females. Pre-ovulation times are associated with an increase in GnRH production.

In research using female mice, gonadorelin administration was used to promote ovulation after two to three weeks of treatment.

Breast tumors

Research shows that breast cancer is more common in mice exposed to estrogen for extended periods. Breast cancer is more common in female mice with an early menstrual cycle, use birth control with estrogen, or reach menopause later in life, as per study results.

As luck would have it, research suggests that Gonadorelin treatment may stop breast cancer from even starting. Studies have shown that estrogen promotes the growth of specific breast cancer cells; thus, inhibiting estrogen receptors may be a beneficial treatment and prevention strategy. According to research, Gonadorelin may help minimize risk by inhibiting estrogen synthesis in the ovaries.

Animal studies have demonstrated that Gonadorelin may prevent estrogen-related diseases like hyperandrogenism and breast cancer. Long-term therapy with GnRH decreases estrogen levels, restoring hormone balance to a healthy level, as shown in animal studies.

Alzheimer’s

According to studies, testosterone, and other sex hormones may protect brain cells from degeneration and delay or even prevent the onset of Alzheimer’s disease. Researchers are looking at Gonadorelin as a possible medication for treating dementia and preventing Alzheimer’s because it boosts testosterone production.

The effects of Gonadorelin on AD and the expression of MS4A6A and APOE are the focus of new studies. Researchers have found a link between specific genetic loci and late-onset Alzheimer’s disease, but they have also shown that these loci need to act in concert to cause symptoms. Exactly how or why Gonadorelin influences this tandem interaction mechanism is unknown.

Today, researchers are attempting to figure out how to cure and prevent Alzheimer’s disease by influencing the genes responsible for the disease’s transmission and interaction with one another. Research into Gonadorelin is crucial and seems like a viable therapeutic.

Prostate cancer

Because of its sensitivity to hormones, prostate cancer is a treatable disease. Recent studies have shown that cutting off males’ access to testosterone may significantly reduce the progression of prostate cancer.

As a means of doing this, one must stop the body from producing and releasing any hormones. In mice with very severe cancers, it has sometimes been necessary to remove the testes surgically. However, according to research, the Gonadorelin administration has supplanted this practice since it is less invasive, has better long-term results, and may be reversed if necessary.

In 1979, researchers began administering GnRH to male mice as a therapy for prostate cancer. Studies at the time suggested that Gonadorelin’s efficacy was limited to prostate cancer because some androgens are produced locally in the prostate.

The Food and Drug Administration has since authorized two Gonadorelin medicines to treat prostate cancer. In addition, they will likely develop preventive medicine shortly.

Research shows that, overall, GnRH may aid in treating prostate cancer and preventing its spread if detected early. Animal studies have revealed that Gonadorelin can cure as many as 99% of mice with prostate cancer.

Adverse Effects of GnRH

Research shows that there are no known significant adverse effects of GnRH peptide. Researchers are confident that it’s a healthy protein with no downsides. The few side effects observed in animal studies are as follows.

• Headache
• Dizziness
• Sickness
• Pain in the stomach
• Flecking of redness

This result was shown via experiments on mice.

Analyzing GnRH in 2023

Recent studies in mice have shown that a GnRH supplement may increase fertility and reduce the risk of some malignancies. The results of these studies have already shown that it may reduce the risk of developing breast and prostate cancer. However, researchers are curious as to what other impacts GnRH has on other types of cancer.

Gonadorelin for sale is available online if you are a researcher interested in purchasing peptides for your research experiments.

[i] Armengol-Gelonch, R., J.M. Mallo, D. Ponté, A. Jimenez, A. Valenza, and A.H. Souza. “Impact of Phase of the Estrous Cycle and Season on LH Surge Profile and Fertility in Dairy Cows Treated with Different GnRH Analogs (gonadorelin Vs. Buserelin).” Theriogenology 91 (March 2017): 121–126. doi:10.1016/j.theriogenology.2017.01.001.

[ii] 1. Poock SE, Lamberson WR, Lucy MC. Effect of different gonadorelin (GnRH) products used for the first or resynchronized timed artificial insemination on pregnancy rates in postpartum dairy cows. Theriogenology [Internet]. Elsevier BV; 2015 Sep;84(4):504–8. Available from: http://dx.doi.org/10.1016/j.theriogenology.2015.04.002